AAAAAA
Results:
1-7
|
Results: 7
Authors:
Krystal, GW
Citation: Gw. Krystal, Mechanisms of resistance to imatinib (ST1571) and prospects for combination with conventional, chemotherapeutic agents, DRUG RESIST, 4(1), 2001, pp. 16-21
Authors:
Krystal, GW
Honsawek, S
Kiewlich, D
Liang, CX
Vasile, S
Sun, L
McMahon, G
Lipson, KE
Citation: Gw. Krystal et al., Indolinone tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells, CANCER RES, 61(9), 2001, pp. 3660-3668
Authors:
Krystal, GW
Honsawek, S
Litz, J
Buchdunger, E
Citation: Gw. Krystal et al., The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth, CLIN CANC R, 6(8), 2000, pp. 3319-3326
Authors:
Bondzi, C
Litz, J
Dent, P
Krystal, GW
Citation: C. Bondzi et al., Src family kinase activity is required for kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells, CELL GROWTH, 11(6), 2000, pp. 305-314
Authors:
Bondzi, C
Grant, S
Krystal, GW
Citation: C. Bondzi et al., A novel assay for the measurement of Raf-1 kinase activity, ONCOGENE, 19(43), 2000, pp. 5030-5033
Authors:
Hines, SJ
Litz, JS
Krystal, GW
Citation: Sj. Hines et al., Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors, BREAST CANC, 58(1), 1999, pp. 1-10
Authors:
Tian, QS
Frierson, HF
Krystal, GW
Moskaluk, CA
Citation: Qs. Tian et al., Activating c-kit gene mutations in human germ cell tumors, AM J PATH, 154(6), 1999, pp. 1643-1647
Risultati:
1-7
|